Through our firm’s global platform, we have represented across practice areas a wide range of companies in the pharmaceutical, biologic, and medical device industries—including large US and international pharmaceutical companies and their subsidiaries, startup and mature biopharmaceutical and biotechnology companies, large medical device manufacturers, as well as the various investors and academic and research institutions that interface with them.
Our capabilities span the entire spectrum of legal needs allowing us to provide integrated advice that results in efficiencies of both cost and precious management time. Underpinning our work is a deep understanding of the device and pharmaceutical markets from first-hand knowledge and in many instances in-house experience.
Our work includes matters involving:
Transactions and strategic alliances
Intellectual property
Healthcare regulation and compliance
Research and clinical trials
Privacy and data monetization
Food and Drug Administration
Antitrust and competitor challenges
Litigation and insurance coverage
Export controls
Foreign Corrupt Practices Act
Patents and Hatch-Waxman cases
Product liability
Our interdisciplinary team is a network of more than 100 lawyers experienced in solving the complex legal and regulatory issues facing pharmaceutical, biotechnology, healthcare, and medical device companies around the world. We apply cutting-edge technological and business savvy to these rapidly evolving sectors within the global healthcare industry.
We have structured some of the largest and most sophisticated drug development deals in the world. We negotiate technology transfers, research and development licenses, joint venture, and other collaborative arrangements, as well as marketing, supply, and distribution deals for clients across these industries. We help protect and enforce intellectual property rights worldwide using our technical training and experience in a wide variety of scientific disciplines. We understand the need for a close working relationship with our client’s management and scientific teams at all stages of research, development, licensing and marketing of their technology, products, and services. We frequently represent venture capital investors in evaluating the intellectual property of potential portfolio companies. Many of our lawyers have worked in clinical and research laboratories, hospitals, or in pharmaceutical and other healthcare companies and have an appreciation of the business dynamics that must be considered when developing workable solutions to complex business issues.
Additionally, we represent major universities, academic medical centers, and research institutions in connection with protection and licensing of intellectual property, Bayh-Dole issues, National Institute of Health and other federal grants, and Institutional Review Board research oversight. Our Corporate and Tax lawyers are experienced as to the issues surrounding formation of new research institutes, as well as state, municipal, and private bond offerings on behalf of educational institutions. We regularly represent technology companies who sponsor research at, or acquire technology from, academic and research institutions and government laboratories.
Lastly, our team is client-focused and practical in its approach. We strive to understand our clients’ goals so that we can efficiently tailor the use of our global platform to achieve those goals in a manner that addresses all relevant legal and regulatory issues.
On Monday, 16 June 2025, the Senate Finance Committee released its version of the Section 899 retaliatory tax provisions that also are included in the “One Big Beautiful Bill Act” that was passed by the House of Representatives on 22 May 2025.
This alert describes the persons who would be subject to the changes contained in Code Section 899, the consequences of being subject to this proposed new Code section, and some of the impacts this provision would have on certain cross-border transactions.
Retaliatory tax provisions contained in H.R. 1, the “One Big Beautiful Bill Act” that recently passed the US House of Representatives, if enacted, would drastically impact common cross-border transactions, including US operations of foreign multinational groups and inbound investments.
The Trump administration has identified growth in the nuclear energy industry as a critical component of the President’s campaign to establish American energy dominance and meet the rapidly increasing need for power.
We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.
